Recruitment

Recruitment Status
Completed
Estimated Enrollment
30

Inclusion Criteria

Platelet count ≥ 100,000/mm³;
Serum creatinine < 1.5 x upper limit of normal (ULN);
Hemoglobin > 10g/dL;
...
Platelet count ≥ 100,000/mm³;
Serum creatinine < 1.5 x upper limit of normal (ULN);
Hemoglobin > 10g/dL;
Age ≥18 years;
Signature of the Informed Consent Form before the performing of any procedures related to the study;
Histologically confirmed metastatic malignant neoplasia;
Serum aspartate aminotransaminase (AST), alanine aminotransferase (ALT) and alkaline phosphatase < 2.5 x upper limit of normal (ULN);
White blood cells ≥ 3.000/μL;
Karnofsky performance status ≥ 70%.

Exclusion Criteria

Received any systemic chemotherapy or radiotherapy within 15 days prior to the blood sample collection;
Presence of autoimmune disorders or conditions that require systemic treatment with immunosuppressant medications or systemic corticosteroids;
Received any immunotherapy within 4 weeks prior to the blood sample collection;
...
Received any systemic chemotherapy or radiotherapy within 15 days prior to the blood sample collection;
Presence of autoimmune disorders or conditions that require systemic treatment with immunosuppressant medications or systemic corticosteroids;
Received any immunotherapy within 4 weeks prior to the blood sample collection;
Known history of positive serology for HIV (human immunodeficiency virus).

Summary

Conditions
Metastatic Cancer
Type
Observational
Design
  • Observational Model: Case-Only
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

The DCs will be generated in vitro from peripheral blood mononuclear cells (PBMCs) which will be obtained from 30 ml of peripheral blood collected from each patient with metastatic cancer by venipuncture in heparin tubes. The cellular viability, the expression of maturation biomarkers and the presen...

The DCs will be generated in vitro from peripheral blood mononuclear cells (PBMCs) which will be obtained from 30 ml of peripheral blood collected from each patient with metastatic cancer by venipuncture in heparin tubes. The cellular viability, the expression of maturation biomarkers and the presence of several cytokines will be evaluated by flow cytometric assays after the culture period of DCs exposed to the peptides. An interim analysis is programmed with the first 10 patients. If an effect is demonstrated the study will include an additional number of subjects sufficient to ensure adequate comparison with other commercially available peptides.

Inclusion Criteria

Platelet count ≥ 100,000/mm³;
Serum creatinine < 1.5 x upper limit of normal (ULN);
Hemoglobin > 10g/dL;
...
Platelet count ≥ 100,000/mm³;
Serum creatinine < 1.5 x upper limit of normal (ULN);
Hemoglobin > 10g/dL;
Age ≥18 years;
Signature of the Informed Consent Form before the performing of any procedures related to the study;
Histologically confirmed metastatic malignant neoplasia;
Serum aspartate aminotransaminase (AST), alanine aminotransferase (ALT) and alkaline phosphatase < 2.5 x upper limit of normal (ULN);
White blood cells ≥ 3.000/μL;
Karnofsky performance status ≥ 70%.

Exclusion Criteria

Received any systemic chemotherapy or radiotherapy within 15 days prior to the blood sample collection;
Presence of autoimmune disorders or conditions that require systemic treatment with immunosuppressant medications or systemic corticosteroids;
Received any immunotherapy within 4 weeks prior to the blood sample collection;
...
Received any systemic chemotherapy or radiotherapy within 15 days prior to the blood sample collection;
Presence of autoimmune disorders or conditions that require systemic treatment with immunosuppressant medications or systemic corticosteroids;
Received any immunotherapy within 4 weeks prior to the blood sample collection;
Known history of positive serology for HIV (human immunodeficiency virus).

Tracking Information

NCT #
NCT02159937
Collaborators
Not Provided
Investigators
Study Chair: José AM Barbuto, Ph.D Departamento de Imunologia - Instituto de Ciências Biomédicas da Universidade de São Paulo
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2023